Precigen posts $20.1 million Q2 net income as PAPZIMEOS revenue hits $53.1 million
Precigen reported second quarter 2026 total revenues of $55.0 million, up from $856,000 a year earlier, driven by commercial sales of PAPZIMEOS, and net income of $20.1 million, or $0.05 per diluted share, compared with a net loss of $26.6 million a year earlier. The company said the quarter marked its first profitable quarter and that cash, cash equivalents and investments of $38.7 million as of June 30, 2026 are expected to support cash flow break-even by the end of 2026.
Key points
- Q2 2026 total revenues were $55.0 million, including $53.1 million from PAPZIMEOS sales, versus $856,000 in Q2 2025.
- Q2 2026 net income was $20.1 million, or $0.06 per basic and $0.05 per diluted share, compared with a net loss of $26.6 million in Q2 2025.
- SG&A expenses rose $6.1 million year over year, mainly from PAPZIMEOS commercial activities; R&D fell $4.2 million, mainly from an accounting change for PAPZIMEOS manufacturing costs.
- Cash, cash equivalents and investments totaled $38.7 million as of June 30, 2026, and the company expects cash flow break-even by the end of 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.